ProCE Banner Activity

TROPION-Lung02: Datopotamab Deruxtecan + Pembrolizumab ± Platinum Chemotherapy in Advanced NSCLC

Conference Coverage
Slideset

Datopotamab deruxtecan plus pembrolizumab with or without platinum chemotherapy showed promising antitumor activity with no unexpected toxicities in patients with advanced NSCLC.

Released: June 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure